Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Limited (NASDAQ: BNR) is a cancer diagnostics company focused on applying next generation sequencing (NGS) technology to precision oncology. The BNR news stream features company announcements on therapy selection testing, early cancer detection programs, pharmaceutical collaborations and financial performance.
In its press releases, Burning Rock regularly reports quarterly and annual financial results, with details on revenues from its central laboratory business, in-hospital business and pharma research and development services. These updates often include commentary on gross margins, operating expenses, and the mix of revenue from Mainland China and overseas customers.
News about Burning Rock also covers scientific and clinical milestones. The company highlights study results on circulating tumor DNA (ctDNA), minimal residual disease (MRD) monitoring, and multi-cancer early detection, presented at major conferences and in journals. It reports on the progress of products such as OncoScreen™ Plus, the CanCatch® Custom MRD assay, and multi-omics early detection tests that have advanced into clinical validation.
Another key theme in BNR news is companion diagnostics and pharmaceutical partnerships. Burning Rock has announced CDx collaborations, regulatory approvals such as the OncoGuide™ OncoScreen™ Plus CDx System in Japan, and an NMPA-approved NGS-based CDx for EGFR exon 20 insertion mutation in lung cancer. Corporate governance items, including annual general meeting results and auditor appointments, also appear in the company’s news flow.
Investors and healthcare professionals can use this news page to follow Burning Rock’s disclosures on its precision oncology platform, business segment trends, regulatory developments and scientific achievements related to BNR stock.
Burning Rock Biotech Limited (NASDAQ: BNR) announced plans to release its unaudited financial results for Q3 2020 on November 20, 2020, before U.S. market opening. The company anticipates revenues between RMB118 million (US$17.4 million) and RMB123 million (US$18.1 million), indicating a 16.2% year-over-year increase. Following the release, a conference call will be held to discuss the results, along with data on cancer early detection at the ESMO Asia Virtual Congress 2020. The revenue figures are preliminary and subject to change until finalization.
Burning Rock Biotech Limited (NASDAQ: BNR) will participate in the Morgan Stanley Virtual Healthcare Conference on September 17 at 8:00 a.m. Eastern Time. The company's management will engage in a fireside chat, allowing for inquiries through Morgan Stanley sales representatives. Burning Rock specializes in precision oncology using next-generation sequencing (NGS) technology, holding a leading market share in China for NGS-based therapy selection testing with over 185,000 tests conducted. The firm is also advancing NGS-based cancer early detection into clinical validation.
Burning Rock Biotech Limited (NASDAQ: BNR) reported a revenue of RMB107.0 million (US$15.1 million) for Q2 2020, a 26.1% increase year-over-year. The central laboratory revenue surged by 17.7% to RMB74.6 million, while in-hospital revenue grew 69% to RMB27.6 million. Despite increased revenues, the company recorded a net loss of RMB71.1 million, worsening from RMB26.0 million in 2019. Operating expenses rose significantly by 67.3% to RMB151.4 million, driven by higher research and development costs. The company expects full-year 2020 revenues of approximately RMB420 million, indicating a 28% growth in H2 2020.
Burning Rock Biotech Limited (NASDAQ: BNR) plans to announce its second quarter 2020 financial results on August 11, 2020, before the U.S. market opens. Following this, a conference call will take place at 8:00 a.m. ET to discuss the results. The company specializes in next-generation sequencing (NGS) technology for precision oncology, with a significant market presence in China, having completed over 185,000 tests. Burning Rock is committed to innovative NGS testing products and has received key certifications in laboratory quality systems.
On June 29, 2020, Burning Rock Biotech (NASDAQ: BNR) announced a strategic partnership with CStone Pharmaceuticals to co-develop companion diagnostics for pralsetinib, aimed at detecting RET alterations in cancer patients in China. Pralsetinib, an investigational therapy by Blueprint Medicines, has shown promising clinical results, particularly in RET fusion-positive non-small cell lung cancer. Burning Rock is committed to advancing precision diagnostics leveraging next-generation sequencing technology, enhancing patient targeting for therapies.
Burning Rock Biotech Limited (NASDAQ: BNR) announced the full exercise of an over-allotment option in its IPO, allowing for the sale of an additional 2,025,000 American Depositary Shares (ADSs) at US$16.50 each. The total offering size now stands at approximately US$281.2 million. The company has a total of 103,804,534 ordinary shares post-offering, including 86,479,686 Class A shares. The IPO is facilitated by underwriters Morgan Stanley, BofA Securities, and Cowen.